Dietary Lipid Sequestration and Metabolic Rewiring in Colorectal Cancer: New Mechanistic Frontiers and Therapeutic Potential

Highlights

• Extrinsic long-chain polyunsaturated fatty acids (PUFAs), notably arachidonic acid, are preferentially sequestered from the intestinal lumen into colorectal cancer (CRC) tissues.
• Accumulation is significantly more pronounced in right-sided CRC, presenting a unique metabolic signature that is independent of sex, disease onset, or traditional molecular subtypes.
• The gut microbiome acts as a critical modulator; germ-free models exhibit reduced tumor burden and improved survival, suggesting a synergistic relationship between microbiota and lipid flux.
• Inhibiting fatty acid (FA) import or mitochondrial β-oxidation successfully suppresses CRC cell proliferation, identifying FA transporters as high-value therapeutic targets.

Background

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. While much of the historical research has focused on genomic instability and signaling pathways like Wnt/β-catenin, the metabolic reprogramming of CRC has emerged as a critical hallmark of progression. Traditionally, the “Warburg effect” emphasized glucose and glutamine as the primary fuels for cancer; however, recent evidence indicates that lipid metabolism plays an equally vital role in supporting the rapid proliferation and structural integrity of tumor cells.

In particular, pro-inflammatory mediators derived from arachidonic acid (an omega-6 polyunsaturated fatty acid) have long been implicated in CRC pathogenesis. While it was previously assumed that these lipids were primarily synthesized de novo or released from membrane stores, the direct uptake of extrinsic (dietary) lipids from the intestinal lumen—the very environment the tumor inhabits—has remained under-explored. This review synthesizes groundbreaking findings from the Gut 2026 study by Janssen et al., which clarifies how CRC cells exploit luminal lipids to fuel their progression.

Key Content

Quantitative Evidence of Lipid Accumulation

The foundational evidence for extrinsic lipid uptake comes from sophisticated mass spectrometry-based lipidomics. In a discovery cohort of 152 patients, total fatty acids were quantified in both non-diseased mucosa and cancerous tissue. These results were validated in an independent cohort (n=28). The data revealed a significant enrichment of long-chain PUFAs, specifically arachidonic acid, within tumor tissues compared to adjacent normal mucosa.

Critically, this lipid profile was found to be independent of several traditional clinical variables, including the patient’s sex, molecular subtypes (such as Microsatellite Instability status), and whether the cancer was of early- or late-disease onset. This suggests that extrinsic lipid sequestration is a fundamental biological feature of CRC rather than a secondary effect of specific genetic mutations.

Anatomical Divergence: The Right-Sided Predominance

One of the most striking findings in recent clinical lipidomics is the anatomical variation in lipid uptake. Accumulation was significantly higher in right-sided (proximal) tumors compared to left-sided (distal) tumors. Right-sided CRC is clinically distinct, often associated with a poorer prognosis and a different mutational landscape. The discovery that these tumors are more adept at sequestering extrinsic FAs provides a potential metabolic explanation for their aggressive behavior and suggests that right-sided tumors may be particularly sensitive to therapeutic interventions targeting lipid import.

Mechanistic Insights from the Apc1638N Mouse Model

To confirm that these lipids are indeed absorbed from the diet and not merely synthesized within the body, researchers utilized the genetic mouse model Apc1638N. By administering stable isotope-labelled fatty acids directly into the intestinal lumen, the flux of these molecules could be tracked.

The study confirmed that labeled FAs were rapidly and selectively absorbed into tumor cells. This process bypasses the systemic circulation to some extent, as the tumors directly “scavenge” the lipids from the fecal stream or luminal contents. This direct absorption pathway underscores the metabolic flexibility of CRC cells in nutrient-poor or competitively crowded microenvironments.

The Microbiome-Lipid Axis

The interaction between the gut microbiome and the host is central to CRC. Comparative studies between specific pathogen-free (SPF) mice and germ-free (GF) Apc1638N mice provided startling insights. In the absence of a microbiome, the development of tumors was significantly curtailed, and overall survival increased. This implies that the microbiome may facilitate the bioavailability or the uptake of pro-tumorigenic lipids, or perhaps that the lipids themselves alter the microbiome to favor a pro-carcinogenic environment. The reduction of extrinsic lipid accumulation in GF models points toward a symbiotic link between bacteria and tumor lipid metabolism.

Functional Impact on Proliferation

Does this accumulation actually drive cancer? Experimental evidence from 2D and 3D cell models (organoids) demonstrated that the inhibition of FA import (using transporters like CD36 or the SLC27/FATP family) or the blocking of β-oxidation (the process of breaking down FAs for energy) led to a marked reduction in cancer cell proliferation. This confirms that extrinsic lipids are not just metabolic waste or bystanders; they are functional drivers of the cell cycle in CRC.

Expert Commentary

The shift toward understanding extrinsic lipid flux represents a significant evolution in oncology. For clinicians, the anatomical correlation (right-sided bias) is particularly relevant, as it may influence future dietary recommendations for patients at high risk of recurrence.

However, several controversies remain. While arachidonic acid is a known precursor to pro-inflammatory prostaglandins (like PGE2), the exact role of other sequestered lipids remains less clear. Furthermore, the interplay with the microbiome suggests that “metabolic therapy” for CRC cannot be done in isolation; it must consider the microbial landscape. There is a potential limitation in translating mouse model survival data (GF vs. SPF) to humans, given the vast complexity of the human diet and microbiota compared to controlled lab environments. Nevertheless, targeting lipid transporters like CD36—which is already being investigated in other metastatic cancers—now appears to be a highly promising avenue for CRC.

Conclusion

The accumulation of extrinsic lipids, particularly arachidonic acid, is a defining metabolic hallmark of colorectal cancer. This process is most pronounced in right-sided tumors and is modulated by the gut microbiome. By demonstrating that tumor proliferation depends on both the import and oxidation of these lipids, recent research provides a clear rationale for developing new therapeutic strategies. Future research should prioritize clinical trials investigating lipid-transporter inhibitors and the impact of specific lipid-restricted diets in conjunction with microbiome modulation to improve outcomes in CRC patients.

References

• Janssen KP, Basic M, Bolsega S, et al. Extrinsic lipids are absorbed and accumulate in colorectal cancer. Gut. 2026;75(4). PMID: 41856524.
• Liebisch G, et al. Lipidomics analysis of human colorectal cancer: systematic review and clinical implications. J Lipid Res. 2024.
• Clavel T, et al. The role of the gut microbiota in dietary lipid metabolism and colon carcinogenesis. Nature Reviews Gastroenterology & Hepatology. 2025.